Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
Status:
Withdrawn
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
Currently, diabetic macular edema is treated is through injection of a medications such as
off-label bevacizumab, which decreases the swelling in the retina. These injections are
sometimes required monthly until the condition is controlled. Recently, there have been some
new FDA approved treatments using laser that decrease the swelling. These approximately ten
minute treatments do not require injections and don't cause permanent damage to the eye, and
they may decrease the number of injections one needs to get to treat diabetic macular edema
(DME).
The purpose of this randomized clinical trial is to determine whether subvisible laser in
combination with intravitreal bevacizumab is non-inferior compared to current standard of
care (intravitreal bevacizumab alone) in achieving favorable outcomes for visual acuity, mean
macular thickness, and patient quality of life, and has fewer needed intravitreal bevacizumab
injections throughout the course of the 12 month study period.